<DOC>
	<DOCNO>NCT02129725</DOCNO>
	<brief_summary>Our research proposal determine PDE-5 inhibition exert favorable effect insulin signal pathway skeletal muscle subject impair fast glucose and/or impair glucose tolerance .</brief_summary>
	<brief_title>Effect Prolonged PDE-5 Inhibition Insulin Signaling Skeletal Muscle .</brief_title>
	<detailed_description>Participants enrol study title `` Renin-angiotensin fibrinolysis interaction human : effect long-term PDE5 inhibition glucose Homeostasis , ( Specific aim 2 ) '' offer opportunity participate sub-study . We obtain skeletal muscle biopsy 16 subject enrol specific aim 2 . Eight subject sildenafil group 8 subject placebo group .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Age &gt; 18 year BMI &gt; 25 kg/M2 ( &gt; 23 kg/M2 among Asian Americans ) â‰¤40kg/m2 Impaired fast glucose ( 100125mg/dL ) and/or impair glucose tolerance ( 2hr plasma glucose 140199 mg/dL ) and/or hemoglobin A1c 5.76.4 % Diabetes type 1 type 2 , define fast glucose 126 mg/dL great , twohour plasma glucose 200 mg/dL great , use antidiabetic medication . The use nitrate disease might require use nitrate . The use potent CYP3A4 inhibitor . Subjects participated weightreduction program last 6 month whose weight increase decreased 2 kg precede 6 month . Pregnancy . Women childbearing potential require undergone tubal ligation use barrier hormonal method birth control . Breastfeeding . Cardiovascular disease myocardial infarction within 6 month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy . Treatment anticoagulant . Treatment metformin . History serious neurologic disease cerebral hemorrhage , stroke , transient ischemic attack . History presence immunological hematological disorder . Diagnosis asthma current inhale corticosteroid therapy . Clinically significant gastrointestinal impairment could interfere drug absorption . Impaired hepatic function ( aspartate amino transaminase and/or alanine amino transaminase &gt; 1.5 x upper limit normal range ) Impaired renal function ( serum creatinine &gt; 1.5 mg/dl ) . Hematocrit &lt; 35 % . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult . Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) . Treatment lithium salt . History alcohol drug abuse . Treatment investigational drug 1 month precede study . Mental condition render subject unable understand nature , scope possible consequence study . Inability comply protocol , e.g . uncooperative attitude , inability return followup visit , unlikelihood completing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>